Can one dose of psilocybin treat depression?
A single 25mg dose of psilocybin, given with psychological support, lowered depression scores by 12.3 points more than an active placebo at 6 weeks. In a phase 2 randomized trial of 104 adults with major depressive disorder, 41.7% on psilocybin met the trial’s definition of sustained response versus 11.4% on placebo.
Psilocybin was compared against 100mg of niacin, an active placebo, in identical-appearing capsules. Both groups received the same psychological support, and participants, site staff, the sponsor, the central raters scoring symptoms, and the statisticians were all blinded to assignment.
What the data show:
- Effectiveness: MADRS scores fell by a mean of 19.1 points with psilocybin versus 6.8 points with placebo from a baseline near 35, a difference of -12.3 points (95% CI, -17.5 to -7.2; p < .001) at day 43
- Speed: The separation was already -12.0 points at day 8 (95% CI, -16.6 to -7.4; p < .001) and held at day 15 and day 29
- Response rates: Sustained response in 20 of 48 psilocybin participants (41.7%) versus 5 of 44 on placebo (11.4%), a difference of 30.3 percentage points (95% CI, 13.5 to 47.1; p = .002)
- Study scope: Randomized, blinded, placebo-controlled trial of 104 patients (51 psilocybin, 53 niacin) over 6 weeks at 11 US research sites
- Safety: No serious treatment-emergent adverse events, though 82% of psilocybin participants had a drug-related adverse event versus 44% on placebo, most of them mild
This JAMA trial tested a single 25mg dose of synthetic psilocybin administered with psychological support in adults with moderate or greater major depressive disorder, and tracked them for 6 weeks with blinded central raters.
Dr. Kumar’s Take
A single dose that still shows a 12-point MADRS separation six weeks later does not fit the model of antidepressant treatment I trained under, where daily dosing for weeks is the price of admission. The effect here appeared by day 8 and was still there at day 43, and it showed up on function as well as mood, which matters more to me than symptom scores alone. I read this as a serious signal rather than a finished answer: 104 patients, 6 weeks, and a treatment that only works inside a structured session with trained staff. The design is the strongest part. Blinded central raters and an active placebo address the two criticisms that have dogged this field.
Study Snapshot
This phase 2 randomized, blinded, placebo-controlled trial enrolled 104 adults with major depressive disorder at 11 US sites between December 2019 and June 2022. Eligible participants were medically healthy adults aged 21 to 65 with a DSM-5 diagnosis of MDD, a current episode of at least 60 days, and a central rater MADRS total score of 28 or higher at screening. Participants on psychotropic medication could enroll after a taper. Participants were randomized 1:1 to a single 25mg oral dose of psilocybin or a 100mg dose of niacin in identical-appearing capsules, each given with psychological support. The primary outcome was change in MADRS score (range 0 to 60) from baseline to day 43, with assessments at days 2, 8, 15, 29, and 43.
Results in Real Numbers
The trial randomized 104 participants, 51 to psilocybin and 53 to niacin placebo. Mean age was 41.1 years (SD 11.3) and 52 (50%) were women. Baseline MADRS scores averaged 35.5 in the psilocybin group and 35.0 in the placebo group. Median length of the current depressive episode was 53 weeks with psilocybin and 81 weeks with placebo, and 14% and 11% respectively met criteria for treatment-resistant depression. Before dosing, participants completed 6 to 8 hours of preparation.
At day 43, the primary endpoint, MADRS scores had fallen by a mean of 19.1 points (95% CI, -22.7 to -15.5) with psilocybin versus 6.8 points (95% CI, -10.5 to -3.1) with placebo, a mean difference of -12.3 points (95% CI, -17.5 to -7.2; p < .001). The separation appeared early and held: -12.0 points at day 8 (p < .001), -11.1 points at day 15, and -13.7 points at day 29. There was no difference at day 2 (-0.1 points, p = .95).
Sustained response, defined by MADRS across the follow-up visits, occurred in 20 of 48 psilocybin participants (41.7%) versus 5 of 44 placebo participants (11.4%), a difference of 30.3 percentage points (95% CI, 13.5 to 47.1; p = .002). Sustained remission occurred in 12 of 48 (25.0%) versus 4 of 44 (9.1%), a difference of 15.9 points (95% CI, 1.0 to 30.8; p = .05). The authors report the response finding as significant but not the remission finding.
Function improved as well. Sheehan Disability Scale scores fell by a mean of 4.07 points with psilocybin versus 1.76 points with placebo at day 43, a difference of -2.31 (95% CI, -3.50 to -1.11; p < .001).
On safety, no serious treatment-emergent adverse events occurred. 88% of psilocybin participants had at least one adverse event versus 61% on placebo, and 82% had at least one drug-related adverse event versus 44%. Drug-related events were mild in 78% of the psilocybin group and moderate in 22%; 8% had a severe drug-related event, and the authors report a higher rate of severe adverse events with psilocybin. The most common effects were headache (66% versus 24%), nausea (48% versus 6%), and visual perceptual effects on dosing day (44% versus 6%). Visual perceptual effects after the dosing day were reported by 6% in each group. Adverse events requiring psychiatric attention occurred in 2 psilocybin participants (4%) and 1 placebo participant (2%).
Who Benefits Most
The trial enrolled adults with moderate or greater major depressive disorder, most of them not treatment resistant by formal criteria, with a median of one prior pharmacological treatment for the current episode. That is a broader population than the treatment-resistant groups studied in much of this field, so the results speak to ordinary major depression, not only to the hardest cases.
Patients willing to engage with an extended preparation and support process are the ones this protocol was built around. Psilocybin here was never a pill alone: every participant received psychological support before and around dosing, and the trial cannot separate the drug from that structure.
Safety, Limits, and Caveats
Psilocybin treatment in this trial required a specialized clinical setting with trained personnel and psychological support. The acute psychoactive effects need monitoring, and the adverse event profile was real: headache and nausea were common, and severe drug-related events occurred in 8% of the psilocybin group.
Follow-up ran 6 weeks, so durability beyond that point is untested here. Exclusions matter for generalizability: personal or first-degree family history of psychosis or mania, moderate or severe alcohol or drug use disorder, active suicidal ideation with intent or plan, suicidal behavior in the past 12 months, and more than 10 lifetime uses of a psychedelic or any use in the past 5 years all ruled participants out. The population was also predominantly white, 86% in the psilocybin group and 96% in the placebo group.
Practical Takeaways
- Psilocybin therapy in this trial required a specialized clinical setting with trained professionals, and it is not something to source or attempt outside that structure
- The treatment model is genuinely different: one supervised session rather than a daily pill
- Psychological support was part of the intervention in both arms, so plan for the preparation and integration work, not just the dose
- Access remains through clinical trials and regulatory pathways, so the practical question for most patients today is trial eligibility
What This Means for Depression Treatment
A single dose producing a 12.3-point MADRS advantage at 6 weeks, with the separation visible by day 8, points toward a treatment model built on intensive single sessions rather than continuous daily dosing. The parallel improvement in Sheehan Disability Scale scores suggests the benefit reached daily function and not only symptom checklists.
The trial also demonstrates that psychological support was inseparable from the intervention. Both arms received it, and the authors frame psilocybin as promising specifically when administered with that support.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
How long do the effects of psilocybin treatment last?
This trial followed participants for 6 weeks after a single dose. The advantage over placebo was present at day 8 and still present at day 43, the primary endpoint.
Is psilocybin therapy safe for depression treatment?
No serious treatment-emergent adverse events occurred in this trial. Side effects were common though: 82% of psilocybin participants had a drug-related adverse event, mostly mild, with headache in 66% and nausea in 48%, and 8% had a severe drug-related event.
How does psilocybin compare with a placebo pill?
The comparator here was 100mg of niacin rather than an inert capsule, in an identical-appearing capsule with identical psychological support. Placebo participants still improved by a mean of 6.8 MADRS points at day 43.
Bottom Line
A single 25mg dose of psilocybin with psychological support reduced depression scores by 12.3 points more than active placebo at 6 weeks and improved functional disability, with no serious treatment-emergent adverse events but a higher rate of adverse events overall. That is a strong 6-week signal in 104 patients, and it belongs in supervised clinical settings while longer-term evidence accumulates.
